Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease

Ramsay, 2018, A perspective on multi-target drug discovery and design for complex diseases, Clin. Transl. Med., 7, 3, 10.1186/s40169-017-0181-2 Alcaro, 2019, Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation, Front. Chem., 7, 71, 10.3389/fchem.2019.00071 Laura Bolognesi, 2011, Multitarget-Directed Ligands: Innovative Chemical Probes and Therapeutic Tools Against Alzheimer’s Disease, Curr. Top. Med. Chem., 11, 2797, 10.2174/156802611798184373 Zhou, 2019, Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms, J. Med. Chem., 62, 8881, 10.1021/acs.jmedchem.9b00017 Morphy, 2005, Designed Multiple Ligands. An Emerging Drug Discovery Paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d Cavalli, 2008, Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem., 51, 347, 10.1021/jm7009364 O’Boyle, 2011, Designed Multiple Ligands for Cancer Therapy, Curr. Med. Chem., 18, 4722, 10.2174/092986711797535344 Maramai, 2020, Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations, BioMed Res. Int., 2020, 5120230, 10.1155/2020/5120230 Prati, 2018, BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease, J. Med. Chem., 61, 619, 10.1021/acs.jmedchem.7b00393 Cummings, 2014, Alzheimer’s disease drug-development pipeline: few candidates, frequent failures, Alzheimers. Res. Ther., 6, 37, 10.1186/alzrt269 Alzheimer’s Association Report, 2019, Alzheimer’s disease facts and figures, Alzheimer’s Dement., 15, 321 Lage, 2006, 100 Years of Alzheimer’s disease (1906–2006), J. Alzheimer’s Dis., 9, 15, 10.3233/JAD-2006-9S303 L.S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto, Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014, J. Intern. Med. 275 (2014) 251–283. doi:10.1111/joim.12191. Matsunaga, 2015, Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis, PLoS One., 10, 10.1371/journal.pone.0123289 Howard, 2012, Donepezil and Memantine for Moderate-to-Severe Alzheimer’s Disease, N. Engl. J. Med., 366, 893, 10.1056/NEJMoa1106668 J. Cummings, G. Lee, A. Ritter, M. Sabbagh, K. Zhong, Alzheimer’s disease drug development pipeline: 2019, Alzheimer’s Dement. Transl. Res. Clin. Interv. 5 (2019) 272–293. doi:10.1016/j.trci.2019.05.008. R. Iizuka, H. Arai, Neurotransmitter Changes in Alzheimer-Type Dementia and Therapeutic Strategies, in: Springer, Boston, MA, 1990: pp. 459–464. doi:10.1007/978-1-4684-5844-2_91. Davies, 1976, Selective loss of central cholinergic neurons in Alzheimer’s Disease, Lancet., 308, 1403, 10.1016/S0140-6736(76)91936-X Pohanka, 2011, Cholinesterases, a target of pharmacology and toxicology, Biomed. Pap., 155, 219, 10.5507/bp.2011.036 Gulisano, 2018, Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade, J. Alzheimer’s Dis., 64, S611, 10.3233/JAD-179935 Castellani, 2006, Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau, Am. J. Alzheimers. Dis. Other Demen., 21, 126, 10.1177/153331750602100213 Ricciarelli, 2017, The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind, Curr. Neuropharmacol., 15, 926, 10.2174/1570159X15666170116143743 Martorana, 2010, Beyond the cholinergic hypothesis: Do current drugs work in alzheimer’s disease?, CNS Neurosci. Ther., 16, 235, 10.1111/j.1755-5949.2010.00175.x Ghamari, 2020, In silico and in vitro studies of two non-imidazole multiple targeting agents at histamine H3 receptors and cholinesterase enzymes, Chem. Biol. Drug Des., 95, 279, 10.1111/cbdd.13642 Incerti, 2010, Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H3 Receptor Antagonists Combining Anticholinesterase Activity, ChemMedChem., 5, 1143, 10.1002/cmdc.201000008 Bautista-Aguilera, 2017, Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H 3 R Antagonism for Neurodegenerative Diseases, Angew. Chemie Int. Ed., 56, 12765, 10.1002/anie.201706072 Brioni, 2011, Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease, J. Pharmacol. Exp. Ther., 336, 38, 10.1124/jpet.110.166876 Zlomuzica, 2016, Neuronal histamine and cognitive symptoms in Alzheimer’s disease, Neuropharmacology., 106, 135, 10.1016/j.neuropharm.2015.05.007 Raddatz, 2010, Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases, Curr. Top. Med. Chem., 10, 153, 10.2174/156802610790411027 Łazewska, 2014, New developments around histamine H3 receptor antagonists/inverse agonists: A patent review (2010-present), Expert Opin. Ther. Pat., 24, 89, 10.1517/13543776.2014.848197 Black, 2008, Minimization of potential hERG liability in histamine H3 receptor antagonists, Inflamm. Res., 57, 10.1007/s00011-007-0622-2 Celanire, 2005, Keynote review: Histamine H3 receptor antagonists reach out for the clinic, Drug Discov. Today., 10, 1613, 10.1016/S1359-6446(05)03625-1 Grimsby, 1990, Tissue Distribution of Human Monoamine Oxidase A and B mRNA, J. Neurochem., 55, 1166, 10.1111/j.1471-4159.1990.tb03121.x Schedin-Weiss, 2017, Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels, Alzheimer’s Res. Ther., 9, 57, 10.1186/s13195-017-0279-1 Oreland, 1986, Brain and brain monoamine oxidase in aging and in dementia of Alzheimer’s type, Prog. Neuropsychopharmacol. Biol. Psychiatry., 10, 533, 10.1016/0278-5846(86)90023-0 Riederer, 2004, Monoamine Oxidase-B Inhibition in Alzheimer’s Disease, Neurotoxicology., 25, 271, 10.1016/S0161-813X(03)00106-2 Park, 2019, Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease, Sci. Adv., 5, eaav0316, 10.1126/sciadv.aav0316 Borroni, 2017, Sembragiline: A novel, selective monoamine oxidase type b inhibitor for the treatment of Alzheimer’s disease, J. Pharmacol. Exp. Ther., 362, 413, 10.1124/jpet.117.241653 Cummings, 2020, Alzheimer’s disease drug development pipeline: 2020, Alzheimer’s Dement. Transl. Res. Clin. Interv., 6 Pisani, 2011, Targeting Monoamine Oxidases with Multipotent Ligands : An Emerging Strategy in the Search of New Drugs Against, Neurodegenerative Diseases, 4568 Łażewska, 2018, 4-tert-Pentylphenoxyalkyl derivatives – Histamine H3 receptor ligands and monoamine oxidase B inhibitors, Bioorganic Med. Chem. Lett., 28, 3596, 10.1016/j.bmcl.2018.10.048 Łazewska, 2006, Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists, Bioorganic Med. Chem., 14, 3522, 10.1016/j.bmc.2006.01.013 Bajda, 2020, Search for new multi-target compounds against Alzheimer’s disease among histamine H3 receptor ligands, Eur. J. Med. Chem., 185, 10.1016/j.ejmech.2019.111785 Łażewska, 2020, Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer’s Disease, Eur. J. Med. Chem., 207, 10.1016/j.ejmech.2020.112743 Łażewska, 2017, Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligands, Bioorganic Med. Chem., 25, 5341, 10.1016/j.bmc.2017.07.058 Faghih, 2002, Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands, Bioorganic Med. Chem. Lett., 12, 3077, 10.1016/S0960-894X(02)00648-0 Cowart, 2004, A new class of potent non-imidazole H3 antagonists: 2-Aminoethylbenzofurans, Bioorganic Med. Chem. Lett., 14, 689, 10.1016/j.bmcl.2003.11.032 M. Chytil, S.R. Engel, Q.K. Fang, International Application Published Under The PATENT COOPERATION TREATY (PCT); Histamine H3 inverse agonists and antagonists and methods of use thereof. WO2010144571A1, 2010. M. Cowart, Y.-Y. Ku, S.-J. Chang, D. Fernando, T. Grieme, R. Altenbach, Fused bicyclic-substituted amines as histamine-3 receptor ligands. U.S. Pat. Appl. Publ. (2004), US 2004/0224952 A1, 2004. Morini, 2008, Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity, Bioorganic Med. Chem., 16, 9911, 10.1016/j.bmc.2008.10.029 Ellman, 1961, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7, 88, 10.1016/0006-2952(61)90145-9 Sander, 2010, Kojic Acid Derivatives as Histamine H3 Receptor Ligands, Chem. Pharm. Bull. (Tokyo), 58, 1353, 10.1248/cpb.58.1353 Bajda, 2013, Structure-based search for new inhibitors of cholinesterases, Int. J. Mol. Sci., 14, 5608, 10.3390/ijms14035608 Kryger, 1999, Structure of acetylcholinesterase complexed with E2020 (Ariceptρ): Implications for the design of new anti-Alzheimer drugs, Structure., 7, 297, 10.1016/S0969-2126(99)80040-9 Hwang, 2016, Failure of investigational drugs in late-stage clinical development and publication of trial results, JAMA Intern. Med., 176, 1826, 10.1001/jamainternmed.2016.6008 Wiȩckowska, 2020, In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases, ACS Chem. Neurosci., 11, 3793, 10.1021/acschemneuro.0c00489 Podlewska, 2020, In silico and in vitro studies on interaction of novel non-imidazole histamine H3R antagonists with CYP3A4, Bioorganic Med. Chem. Lett., 30, 10.1016/j.bmcl.2020.127147 Percec, 1999, Poly(p-phenylene)s with Mesogenic Side Groups: A Potential Class of NII Side Chain Liquid Crystalline Polymers?, Macromolecules., 32, 2597, 10.1021/ma9900129 Sadek, 2016, Non-imidazole-based histamine H3 receptor antagonists with anticonvulsant activity in different seizure models in male adult rats, Drug Des. Devel. Ther., 10, 3879, 10.2147/DDDT.S116192 Latacz, 2017, In the search for a lead structure among series of potent and selective hydantoin 5-HT 7 R agents: The drug-likeness in vitro study, Chem. Biol. Drug Des., 90, 1295, 10.1111/cbdd.13106 Latacz, 2019, The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment, Int. J. Mol. Sci., 20, 3420, 10.3390/ijms20143420